Literature DB >> 22132727

Evaluation and management of depressive and anxiety symptoms in midlife.

M Hickey1, C Bryant, F Judd.   

Abstract

OBJECTIVES: Evaluation and management of anxiety and depression during the menopausal transition are complicated by the overlap between some symptoms of affective disorder with those of menopausal symptoms, and also by inconsistencies in the literature regarding the relationship between the menopausal transition and affective disorders.
METHODS: We have reviewed key studies over the past three decades addressing depression and anxiety during the menopause transition, in order to present a practical, clinical approach to the evaluation and management of anxiety and depressive symptoms at midlife.
RESULTS: Symptoms of anxiety and depression are common at midlife and may coincide with menopausal symptoms. Some menopausal symptoms are also symptoms of anxiety and/or depression. Management should include treatment of troublesome menopausal symptoms, providing strategies to deal with psychosocial stressors, and exclusion of clinically significant anxiety and depressive disorders. Interventions such as exercise and cognitive behavior therapy may improve mood and general health at menopause, and a multifocal approach is recommended. Depression of greater than moderate severity requires treatment with an antidepressant. Some selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors may also improve vasomotor symptoms and these should be considered in women with both affective disorder and vasomotor symptoms.
CONCLUSIONS: There is no clear evidence that the menopause transition alone increases the risk of clinically significant affective disorders, except in women with risk factors such as psychosocial stressors, severe and prolonged vasomotor symptoms and a previous history of affective disorders. Nevertheless, anxiety and depression are common in women and clinicians should be alert to the symptoms of these conditions at all encounters.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22132727     DOI: 10.3109/13697137.2011.620188

Source DB:  PubMed          Journal:  Climacteric        ISSN: 1369-7137            Impact factor:   3.005


  11 in total

1.  Anxiety as a risk factor for menopausal hot flashes: evidence from the Penn Ovarian Aging cohort.

Authors:  Ellen W Freeman; Mary D Sammel
Journal:  Menopause       Date:  2016-09       Impact factor: 2.953

2.  Does risk for anxiety increase during the menopausal transition? Study of women's health across the nation.

Authors:  Joyce T Bromberger; Howard M Kravitz; Yuefang Chang; John F Randolph; Nancy E Avis; Ellen B Gold; Karen A Matthews
Journal:  Menopause       Date:  2013-05       Impact factor: 2.953

3.  Quality of life among postmenopausal women enrolled in the Minnesota Green Tea Trial.

Authors:  Allison Dostal Webster; Deborah A Finstad; Mindy S Kurzer; Carolyn J Torkelson
Journal:  Maturitas       Date:  2017-11-02       Impact factor: 4.342

Review 4.  Sex differences in anxiety disorders: Interactions between fear, stress, and gonadal hormones.

Authors:  Lisa Y Maeng; Mohammed R Milad
Journal:  Horm Behav       Date:  2015-04-14       Impact factor: 3.587

5.  Effect of Hypnosis on Anxiety: Results from a Randomized Controlled Trial with Women in Postmenopause.

Authors:  R Lynae Roberts; Joshua R Rhodes; Gary R Elkins
Journal:  J Clin Psychol Med Settings       Date:  2021-08-17

6.  Resveratrol ameliorates estrogen deficiency-induced depression- and anxiety-like behaviors and hippocampal inflammation in mice.

Authors:  Tianyao Liu; Yuanyuan Ma; Ruiyu Zhang; Hongyu Zhong; Lian Wang; Jinghui Zhao; Ling Yang; Xiaotang Fan
Journal:  Psychopharmacology (Berl)       Date:  2019-01-04       Impact factor: 4.530

7.  Estradiol, stress reactivity, and daily affective experiences in trauma-exposed women.

Authors:  Jenna K Rieder; Olena Kleshchova; Mariann R Weierich
Journal:  Psychol Trauma       Date:  2021-10-28

Review 8.  The Antidepressant-like Effects of Estrogen-mediated Ghrelin.

Authors:  Pu Wang; Changhong Liu; Lei Liu; Xingyi Zhang; Bingzhong Ren; Bingjin Li
Journal:  Curr Neuropharmacol       Date:  2015       Impact factor: 7.363

9.  Reducing depression during the menopausal transition: study protocol for a randomised controlled trial.

Authors:  Osvaldo P Almeida; Kylie Marsh; Leon Flicker; Martha Hickey; Andrew Ford; Moira Sim
Journal:  Trials       Date:  2014-08-06       Impact factor: 2.279

Review 10.  Sex: A Significant Risk Factor for Neurodevelopmental and Neurodegenerative Disorders.

Authors:  Paulo Pinares-Garcia; Marielle Stratikopoulos; Alice Zagato; Hannah Loke; Joohyung Lee
Journal:  Brain Sci       Date:  2018-08-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.